Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.
Publication
, Journal Article
Raghu, G; Collard, HR; Anstrom, KJ; Flaherty, KR; Fleming, TR; King, TE; Martinez, FJ; Brown, KK
Published in: Am J Respir Crit Care Med
June 1, 2013
Duke Scholars
Published In
Am J Respir Crit Care Med
DOI
EISSN
1535-4970
Publication Date
June 1, 2013
Volume
187
Issue
11
Start / End Page
1272
Location
United States
Related Subject Headings
- Respiratory System Agents
- Respiratory System
- Idiopathic Pulmonary Fibrosis
- Humans
- Endpoint Determination
- Clinical Trials, Phase III as Topic
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Raghu, G., Collard, H. R., Anstrom, K. J., Flaherty, K. R., Fleming, T. R., King, T. E., … Brown, K. K. (2013). Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med, 187(11), 1272. https://doi.org/10.1164/rccm.201304-0712LE
Raghu, Ganesh, Harold R. Collard, Kevin J. Anstrom, Kevin R. Flaherty, Thomas R. Fleming, Talmadge E. King, Fernando J. Martinez, and Kevin K. Brown. “Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.” Am J Respir Crit Care Med 187, no. 11 (June 1, 2013): 1272. https://doi.org/10.1164/rccm.201304-0712LE.
Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, et al. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1272.
Raghu, Ganesh, et al. “Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.” Am J Respir Crit Care Med, vol. 187, no. 11, June 2013, p. 1272. Pubmed, doi:10.1164/rccm.201304-0712LE.
Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE, Martinez FJ, Brown KK. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1272.
Published In
Am J Respir Crit Care Med
DOI
EISSN
1535-4970
Publication Date
June 1, 2013
Volume
187
Issue
11
Start / End Page
1272
Location
United States
Related Subject Headings
- Respiratory System Agents
- Respiratory System
- Idiopathic Pulmonary Fibrosis
- Humans
- Endpoint Determination
- Clinical Trials, Phase III as Topic
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 11 Medical and Health Sciences